Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Hepatitis During Intensive Phase Anti-Tuberculosis Treatment With or Without Adjunctive N-acetylcysteine in At-Risk Patients
TCTR20251107003Phase 2Recruiting
- Sponsor
- Rajavithi Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of acetylcysteine in Tuberculosis (TB) and Drug-induced hepatitis (DILI) (2 arms), sponsored by Rajavithi Hospital. Primary endpoint: Incidence of hepatitis during intensive phase of anti-tuberculosis treatment. Started Aug 2025; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
Tuberculosis (TB)Drug-induced hepatitis (DILI)
Beyond the preview
Go deeper on TCTR20251107003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20251107003.